drugset / Trial / NCT06860984

Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

NCT06860984

Phase 3 Recruiting 44 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.

Timeline

Start
2025-03-10
Primary completion
2026-06-20
Completion
2026-07-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg